REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

On November8, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended September30, 2017. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated November8, 2017, Reporting Third Quarter 2017 Financial and Operating Results.

REGENERON PHARMACEUTICALS INC Exhibit
EX-99.1 2 exhibit991q32017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1  Press Release Regeneron Reports Third Quarter 2017 Financial and Operating Results•Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016•Third quarter 2017 EYLEA global net sales(1) increased 15% to $1.52 billion versus third quarter 2016•Third quarter 2017 GAAP net income per diluted share increased 46% to $3.32 versus third quarter 2016. Third quarter 2017 non-GAAP net income per diluted share increased 27% to $3.99 versus third quarter 2016.•Phase 3 EYLEA PANORAMA study for the treatment of diabetic retinopathy is fully enrolled with U.S. regulatory submission expected in 2018•Appellate court ordered a new trial and vacated permanent injunction in U.S. Praluent® patent caseTarrytown,…
To view the full exhibit click here

About REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.